Mark L. Heiman BA, PhD

Mark L. Heiman, Ph.D. has 20+ years at Eli Lilly & Co where he served as researcher and CSO of obesity drug discovery. He is currently CSO and Vice President of MicroBiome Therapeutics. Mark is a Fellow of the Obesity Society and serves on the SAB of Helmholtz Alliance for Imaging and Curing Environmental Metabolic Diseases (ICEMED) in Munich, Germany. He serves on the editorial boards of Molecular Metabolism and J of Hepatology & Gastroenterology.
Dr. Heiman received his Ph.D. in Physiology from Louisiana State University School of Medicine. His postdoctoral training in neuroendocrinology was at the Indiana University School of Medicine. He joined the faculty of Medicine at Tulane University where he co-discovered the drug Lanreotide before joining Lilly. Mark has authored over 100 scientific papers and is best known for his seminal work performed at Lilly, which defined the key roles for both leptin and ghrelin in regulating energy balance.